JAGX vs. HOOK, RLYB, TPST, SCYX, ASMB, VTVT, MRNS, IFRX, SLS, and MNOV
Should you be buying Jaguar Health stock or one of its competitors? The main competitors of Jaguar Health include Hookipa Pharma (HOOK), Rallybio (RLYB), Tempest Therapeutics (TPST), SCYNEXIS (SCYX), Assembly Biosciences (ASMB), vTv Therapeutics (VTVT), Marinus Pharmaceuticals (MRNS), InflaRx (IFRX), SELLAS Life Sciences Group (SLS), and MediciNova (MNOV). These companies are all part of the "pharmaceutical preparations" industry.
Hookipa Pharma (NASDAQ:HOOK) and Jaguar Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.
63.9% of Hookipa Pharma shares are held by institutional investors. Comparatively, 12.0% of Jaguar Health shares are held by institutional investors. 5.8% of Hookipa Pharma shares are held by insiders. Comparatively, 0.2% of Jaguar Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Hookipa Pharma has a net margin of -88.73% compared to Hookipa Pharma's net margin of -423.11%. Jaguar Health's return on equity of -33.33% beat Hookipa Pharma's return on equity.
Jaguar Health received 1750 more outperform votes than Hookipa Pharma when rated by MarketBeat users. Likewise, 89.12% of users gave Jaguar Health an outperform vote while only 69.11% of users gave Hookipa Pharma an outperform vote.
Hookipa Pharma has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Jaguar Health has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
Hookipa Pharma presently has a consensus price target of $4.67, indicating a potential upside of 465.79%. Given Jaguar Health's higher probable upside, analysts clearly believe Hookipa Pharma is more favorable than Jaguar Health.
Jaguar Health has lower revenue, but higher earnings than Hookipa Pharma.
In the previous week, Hookipa Pharma had 3 more articles in the media than Jaguar Health. MarketBeat recorded 9 mentions for Hookipa Pharma and 6 mentions for Jaguar Health. Jaguar Health's average media sentiment score of 0.45 beat Hookipa Pharma's score of 0.17 indicating that Hookipa Pharma is being referred to more favorably in the media.
Summary
Hookipa Pharma beats Jaguar Health on 11 of the 15 factors compared between the two stocks.
Ad DTI
Most people would never touch this orange powder… would you?
At first glance, it looks like some ordinary “orange” powder…
But in reality, it is a scientific breakthrough in energy technology.
One that could wipe out fossil fuel, coal, and even the “glorified” renewable energy in just a few years.
And right now, governments, institutions, and the elites are jumping on this resource at record pace to the point where we’re starting to run out.
The question is…
Why are the top 1% piling in this much?
And more importantly, what will be the implications of this act by the elites on YOU and of course, the stock market?
Well, all the answers you need are right here
Get Jaguar Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JAGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jaguar Health Competitors List
Related Companies and Tools
